Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 941-628-3 | CAS number: 1263184-87-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 29 Jan 2014 to 28 Feb 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- 21 July 1997
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.5395 (In Vivo Mammalian Cytogenetics Tests: Erythrocyte Micronucleus Assay)
- Version / remarks:
- August 1998
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.12 (Mutagenicity - In Vivo Mammalian Erythrocyte Micronucleus Test)
- Version / remarks:
- 30 May 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- mammalian erythrocyte micronucleus test
Test material
- Reference substance name:
- rac-(1R,4S,4aR,8R,8aS)-9-(dichloromethylidene)-8-hydroxyoctahydro-1,4-methanonaphthalen-5(1H)-one
- EC Number:
- 941-628-3
- Cas Number:
- 1263184-87-7
- Molecular formula:
- C12H14Cl2O2
- IUPAC Name:
- rac-(1R,4S,4aR,8R,8aS)-9-(dichloromethylidene)-8-hydroxyoctahydro-1,4-methanonaphthalen-5(1H)-one
- Test material form:
- solid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- The rat is an animal that has been used for many years as a suitable experimental animal in cytogenetic investigations. There are many data available from such investigations, which may be helpful in the interpretation of results from the micronucleus test.
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 8 to 10 weeks
- Weight at study initiation: 262.7 to 303.0 gram
- Assigned to test groups randomly: yes
- Fasting period before study: no
- Housing: Housed in groups, in Makrolon Type III / IV, with wire mesh top with granulated soft wood bedding.
- Diet: Pelleted standard diet, ad libitum
- Water: Tap water, ad libitum
- Acclimation period: minimum 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 23 – 65
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES:
29 Jan 2014 to 28 Feb 2014
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- - Vehicle used: 1% CMC (carboxymethyl cellulose) suspended in sterile water
- Justification for choice of vehicle: The vehicle was chosen by the Sponsor and due to its relative non-toxicity for the animals and ability to formulate a suitable dosing preparation.
- Concentration of test material in vehicle: 50, 100 and 200 mg/mL
- Amount of vehicle: 10 mL/kg bw
- Lot/batch no.: BCBD7651V (CMC), 134618061 (sterile water) - Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
On the day of the experiment, the test substance was suspended in 1% CMC. An Ultraturrax was used to formulate the test substance in the vehicle. All animals received a single standard volume once orally. The vehicle was chosen by the Sponsor and due to its relative non-toxicity for the animals and ability to formulate a suitable dosing preparation. The oral route was used as this is of relevance to human risk assessment. A correction factor of 1.06 was applied. - Duration of treatment / exposure:
- Sampling of the bone marrow was done 24 and 48 hours after treatment.
- Frequency of treatment:
- The animals received one single oral dose.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- Low dose group
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- Mid dose group
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- Remarks:
- High dose group
- No. of animals per sex per dose:
- Pre-test: 2 males and 2 females for each pre-test
Main experiment: 7 males per group treated with test substance, 5 males per group for negative and positive control - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- - Positive control: cyclophosphamide
- Route of administration: oral
- Doses / concentrations: 20 mg/kg-bw
Examinations
- Tissues and cell types examined:
- Bone marrow erythrocytes
- Details of tissue and slide preparation:
- PRE-EXPERIMENT:
A preliminary study of acute toxicity was performed in both male and female rats (two animals per sex and dose level) under identical conditions as in the mutagenicity study concerning: animal strain, vehicle, route, frequency, and volume of administration.
The animals were treated once orally with the test substance and examined for acute toxic symptoms at intervals of around 0-1 h, 2-4 h, 5-6 h, 24 h, 30 h, and 48 h after administration of the test substance.
The test dose levels were chosen using doses from the following scheme starting at 1250 mg/kg:
5 – 8 – 12.5 – 20 – 32 – 50 – 80 – 125 – 200 – 320 – 500 – 800 – 1250 – 2000 mg/kg bw.
CRITERIA FOR DOSE SELECTION:
It is generally recommended to use the maximum tolerated dose or the highest dose that can be dissolved and administered reproducibly or 2000 mg/kg as the upper limit for non-toxic test substances.
TREATMENT AND SAMPLING TIMES ( in addition to information in specific fields):
Three adequately spaced dose levels spaced by a factor of 2 were applied (500, 1000 and 2000 mg/kg bw), and bone marrow samples were collected at the central sampling interval of 24 h after treatment. For the highest dose level an additional bone marrow sample was taken at 48 h after treatment.
DETAILS OF SLIDE PREPARATION:
The animals were sacrificed using CO2 followed by bleeding. The femora were removed, the epiphyses were cut off and the marrow was flushed out with fetal calf serum using a syringe. The nucleated cells were separated from the erythrocytes using the method of Romagna. The cell suspensions were passed through a column consisting of α-Cellulose and Cellulose. The columns will then be washed with Hank´s buffered saline. The cell suspension was centrifuged at 1500 rpm (390 × g) for 10 minutes and the supernatant was discarded. A small drop of the re-suspended cell pellet was spread on a slide. The smear was air-dried and then stained with May-Grünwald /Giemsa. Cover slips were mounted with EUKITT. At least one slide was made from each bone marrow sample.
METHOD OF ANALYSIS:
Evaluation of the slides was performed using NIKON microscopes with 100× oil immersion objectives. Per animal 2000 polychromatic erythrocytes (PCE) were analysed for micronuclei. To describe a cytotoxic effect the ratio between polychromatic and normochromatic erythrocytes was determined from the same slide and expressed in polychromatic erythrocytes per 2000 erythrocytes. The analysis was performed with coded slides. Immature and mature erythrocytes were identified by their pale and blue to green colour, respectively. Micronuclei are distinguished by being small nuclei separate from and additional to the main nuclei of the cells.
OTHER:
The animals of all dose groups, except the positive control were examined for acute toxic symptoms at intervals of around 0-1 h, 2-4 h, 5-6 h, 24 h, and 48 h after administration of the test substance or the vehicle controls. - Evaluation criteria:
- ACCEPTANCE CRITERIA
The study was considered valid as the following criteria were met:
- at least 5 animals per group could be evaluated.
- PCE to erythrocyte ratio was not less than 20 % of the negative control.
- The positive control showed a statistically significant and biologically relevant increase of micronucleated PCEs compared to the negative control.
EVALUATION OF RESULTS
A test substance is classified as mutagenic if it induces either a dose-related increase or a clear increase in the number of micronucleated polychromatic erythrocytes in a single dose group. Statistical methods (nonparametric Mann-Whitney test) were used as an aid in evaluating the results. However, the primary point of consideration was the biological relevance of the results.
A test substance that fails to produce a biologically relevant increase in the number of micronucleated polychromatic erythrocytes is considered non-mutagenic in this system.
A test substance failing to meet the criteria for a positive or negative response may be judged equivocal in this assay and may be considered for further investigation. - Statistics:
- Statistical methods (nonparametric Mann-Whitney test) were used as an aid in evaluating the results.
Results and discussion
Test results
- Key result
- Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RESULTS OF PRE-EXPERIMENT
In the first pre-experiment 2 male and 2 female animals received a single oral dose of the test substance (1250 mg/kg bw) suspended in 1% CMC (10 mL/kg bw). Two females treated with 1250 mg/kg bw displayed ruffled fur 24 hours post-treatment.
In the second pre-experiment 2 male and 2 female animals received a single oral dose of the test substance (2000 mg/kg bw) suspended in 1% CMC (10 mL/kg bw). The animals treated with 2000 mg/kg bw did not show any clinical symptoms.
On the basis of these data 2000 mg/kg bw, the maximum OECD Guideline recommended dose for this assay was considered suitable. No substantial gender specific differences in toxicity were observed, thus, the main study was performed using male animals only, as permitted by the Guideline.
RESULTS OF DEFINITIVE STUDY
In the main experiment for the different dose groups 7, 7 and 14 males (2 × 7 males per group) received orally a single dose of 500, 1000 and 2000 mg/kg bw test substance suspended in 1% CMC, respectively. The volume administered was 10 mL/kg bw. The animals treated with the test substance or the vehicle (1% CMC) alone did not show any clinical symptoms.
The mean number of polychromatic erythrocytes was not substantially decreased after treatment with the test substance as compared to the mean value of PCEs of the vehicle control, indicating that the test substance did not have any significant cytotoxic properties on the bone marrow (Table 1 in ‘Any other information on results incl. tables’).
In comparison to the corresponding vehicle controls there was no biologically relevant enhancement or statistically significant increase in the frequency of the detected micronuclei at any preparation interval and dose level after administration of the test substance (Table 1 and 2 in ‘Any other information on results incl. tables’).
For all treatment groups the mean values of micronuclei observed after treatment with the test substance were well within the historical vehicle control range (Table 3 in 'Any other information on results incl. tables'). Additionally no dose dependence was observed.
A dose of 20 mg/kg bw cyclophosphamide administered orally was used as positive control which showed a statistically significant increase of induced micronucleus frequency. The volume of the positive control administered was 10 mL/kg bw.
Any other information on results incl. tables
Table 1. Summary of Micronucleus Test Results
test group |
dose mg/kg b.w. |
sampling time (h) |
PCEs with micronuclei (%) |
range |
PCE per 2000 erythrocytes |
negativecontrol |
0 |
24 |
0.210 |
2 - 6 |
1158 |
test substance |
500 |
24 |
0.329 |
2 -11 |
1163 |
test substance |
1000 |
24 |
0.186 |
2 - 8 |
1129 |
test substance |
2000 |
24 |
0.329 |
2 -12 |
1152 |
positive control |
20 |
24 |
1.540 |
17 -49 |
1076 |
negativecontrol |
0 |
48 |
0.190 |
2 - 9 |
1136 |
test substance |
2000 |
48 |
0.186 |
1 - 8 |
1120 |
Table 2. Biometry
Statistical significance at the five per cent level (p < 0.05) for the incidence of micronuclei was evaluated by means of the non-parametric Mann-Whitney test.
Negative control versus test group |
Significance |
p |
500 mg test substance/kg bw; 24 h |
- |
0.1098 |
1000 mg test substance/kg bw; 24 h |
n.t. |
- |
2000 mg test substance/kg bw; 24 h |
- |
0.2058 |
20 mg CPA/kg bw; 24 h |
+ |
0.0040 |
2000 mg test substance/kg bw; 48 h |
n.t. |
- |
+ = significant;
- = not significant;
n.t.= not tested, as the mean micronucleus frequency was not above the vehicle control value
Table 3. Historical Control Data (2009 – 2013)
Micronucleated cells |
Negative Controls |
Positive Controls (CPA) |
Males |
Males |
|
Mean ± SD (%) |
0.196 ± 0.123 |
2.276 ± 1.061 |
Range of mean group value (%) |
0.000 - 0.550 |
0.300 - 5.700 |
Range (individual animal data) |
0 - 11 |
6 - 114 |
No. of Experiments |
36 |
36 |
Applicant's summary and conclusion
- Conclusions:
- In a GLP compliant OECD 474 study under the experimental conditions reported, the test substance did not induce micronuclei as determined by the micronucleus test in the bone marrow cells of the rat. Therefore, the test substance is considered to be non-mutagenic in this bone marrow micronucleus assay.
- Executive summary:
This GLP compliant OECD 474 study was performed in order to investigate the potential of the test substance to induce micronuclei in polychromatic erythrocytes (PCE) in the bone marrow of the rat. The test substance was suspended in 1% carboxymethylcellulose (CMC), which was also used as the vehicle control. The volume administered orally was 10 mL/kg bw. At 24 and 48 hours after a single administration of the test substance, the bone marrow cells were collected for micronuclei analysis. Seven males per test group (except the negative and positive control groups with five males only) were evaluated for the occurrence of micronuclei. Per animal 2000 polychromatic erythrocytes (PCEs) were scored for micronuclei. To describe a cytotoxic effect due to the treatment with the test substance the ratio between polychromatic and normochromatic erythrocytes was determined per slide and reported as the number of PCEs per 2000 erythrocytes. The following dose levels of the test substance were investigated: 24 h preparation interval: 500, 1000, and 2000 mg/kg bw; 48 h preparation interval: 2000 mg/kg bw. The highest dose was estimated to be a suitable maximum tolerated dose based on a pre-experiment.
After treatment with the test substance the number of PCEs per 2000 erythrocytes was not substantially decreased as compared to the mean value of PCEs per 2000 erythrocytes of the vehicle control, thus indicating that the test substance did not exert any significant cytotoxic effects in the bone marrow. In comparison to the corresponding vehicle controls, there was no biologically relevant or statistically significant enhancement in the frequency of the detected micronuclei at any preparation interval after administration of the test substance with any dose level used. For all treatment groups the mean values of micronuclei observed after treatment with the test substance were well within the historical vehicle control range. Additionally, no dose dependency was observed. A dose of 20 mg/kg bw cyclophosphamide administered orally was used as the positive control, which showed a substantial increase of induced micronucleus frequency. The volume of the positive control administered was 10 mL/kg bw.
In conclusion, it can be stated that under the experimental conditions reported, the test substance did not induce micronuclei as determined by the micronucleus test with bone marrow cells of the rat. Therefore, the test substance is considered to be non-mutagenic in this bone marrow micronucleus assay.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
